Arfolitixorin - a drug candidate
for treatment of colorectal cancer

More than 370 000 CRC patients
could be treated
with arfolitixorin

The global Phase III AGENT study

The AGENT study with arfolitixorin

is ongoing at more than 80 hospitals

in The US, Canada, Europe, Australia and Japan

See how arfolitixorin
works in cancer cells

See the animation

Previous

Next

Startpage 2

Press releases & Latest news

The first patient included in Japan in Isofol’s Phase 3 AGENT study

The first patient included in Japan in Isofol’s Phase 3 AGENT study

February 18, 2020 by

GOTHENBURG, Sweden, February 18 2020 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL) today announced that the first…

Empowered patient podcast

Empowered patient podcast

February 12, 2020 by Admin Isofol

Our CEO, Dr. Ulf Jungnelius, was featured on Karen Jagoda’s empowered patient podcast to discuss colorectal cancer and how our…

Gene expression analysis method has been validated by a commercial laboratory

Gene expression analysis method has been validated by a commercial laboratory

January 30, 2020 by

GOTHENBURG, Sweden, January 30, 2020 – Isofol Medical AB (publ) (Nasdaq First North Premier: ISOFOL), today announced that the method …

Upcoming Events

March 03, 2020 - March 04, 2020
Carnegie Nordic Healthcare Seminar, Stockholm
Isofol will attend the "Carnegie Nordic Healthcare Seminar" in Stockholm.
March 04, 2020 - March 04, 2020
Life Science Day, Gothenburg
Isofol will attend the "Life Science Day" i Gothenburg. The event will also be live broadcast.
March 10, 2020 - March 10, 2020
Fight Cancer Seminar, Stockholm
Isofol will attend the "Fight Cancer Seminar" in Stockholm, arranged by RedEye. The event will also be live broadcast.

©2019 Isofol Medical AB (publ) Biotech Center, Arvid Wallgrens Backe 20, SE-413 46 Gothenburg, Sweden.

Isofol´s Glossary

Isofol's website uses cookies to improve and customize your visit. By continuing you accept this.Accept Read More
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are as essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are as essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.

Necessary Always Enabled

Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.